Poor
Not Aligned
Patient Risk:
High
Summary
Several key label-aligned safety and dosing claims were marked unsupported/absent despite relevant label sections being provided in the prompt, and multiple adverse-reaction statements show apparent mis-citation/misattribution risk. Overall alignment is poor.
Category Scores
Accurate Statements
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist.
11 DESCRIPTION
Ozempic has been approved for use in adults with type 2 diabetes.
1 INDICATIONS AND USAGE
Ozempic is effective in improving glycemic control in patients with type 2 diabetes.
1 INDICATIONS AND USAGE
Ozempic reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes.
1 INDICATIONS AND USAGE
Ozempic has been shown to be effective in improving glycemic control and reducing the risk of MACE.
1 INDICATIONS AND USAGE
Unsupported Statements
Ozempic mimics the action of the natural hormone GLP-1.
Not supported by the provided label text sections (no explicit 'mimics' phrasing in supplied excerpts).
GLP-1 regulates blood sugar levels by stimulating insulin release, suppressing glucagon production, and slowing gastric emptying.
Not supported by the provided label excerpts.
Ozempic is administered via injection once a week.
Marked absent in the provided label-section evaluation despite a provided citation to 2 DOSAGE AND ADMINISTRATION; indicates a labeling alignment failure.
A 2020 meta-analysis found Ozempic significantly reduced HbA1c levels compared to placebo.
Marked absent in the provided label-section evaluation (14 CLINICAL STUDIES cited, but '2020 meta-analysis' framing is not supported by the provided excerpts).
A 2020 meta-analysis found Ozempic significantly reduced body weight compared to placebo.
Marked absent in the provided label-section evaluation (14 CLINICAL STUDIES cited, but '2020 meta-analysis' framing is not supported by the provided excerpts).
Common adverse reactions to Ozempic include nausea and vomiting.
Tied to an incorrect/misaligned label citation in the provided evaluation (5.6 cited instead of a section clearly supporting 'common adverse reactions').
Common adverse reactions to Ozempic include diarrhea.
Tied to an incorrect/misaligned label citation in the provided evaluation (5.6 cited instead of a section clearly supporting 'common adverse reactions').
Common adverse reactions to Ozempic include abdominal pain.
Provided label citation is to pancreatitis warnings (5.2), which does not clearly support 'common adverse reactions' wording in the provided excerpts.
Common adverse reactions to Ozempic include injection site reactions.
No supplied label support in provided excerpts/evaluation.
A 2020 study found patients taking Ozempic had a higher risk of pancreatitis compared to those taking placebo.
Marked absent in the provided label-section evaluation despite citing 5.2; '2020 study' comparative framing not supported by the provided excerpts.
A 2020 study found patients taking Ozempic had a higher risk of thyroid C-cell tumors compared to those taking placebo.
Marked absent in the provided label-section evaluation despite citing the boxed warning; provided excerpts do not support comparative 'higher risk vs placebo' attribution.
A 2020 study found patients taking Ozempic had a higher risk of acute kidney injury compared to those taking placebo.
Marked absent in the provided label-section evaluation despite citing 5.6; comparative 'vs placebo' framing not supported by the provided excerpts.
The long-term risks of Ozempic are not yet fully understood.
Not supported by the provided label excerpts.
A 2020 study found patients taking Ozempic for more than 2 years had a higher risk of hypoglycemia compared to those taking placebo.
No supplied label support in provided excerpts/evaluation.
A 2020 study found patients taking Ozempic for more than 2 years had a higher risk of gastrointestinal adverse events compared to those taking placebo.
Marked absent in the provided label-section evaluation despite citing 5.7; comparative/time-duration 'vs placebo' framing not supported by provided excerpts.
Ozempic has been used off-label for weight loss in individuals without diabetes.
Not supported by the provided label excerpts.
Off-label use of Ozempic for weight loss is not approved by regulatory agencies.
Not supported by the provided label excerpts as a specific regulatory-agency statement; label only provides approved indications in supplied excerpt.
Off-label use of Ozempic for weight loss may increase the risk of side effects.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Ozempic is administered via injection once a week.
Label Reference
2 DOSAGE AND ADMINISTRATION (once-weekly dosing is core label information; the evaluation marked this claim absent despite the cited section).
Important Omissions
No contraindication-related statements were included in the extracted claims (e.g., contraindication in patients with personal/family history of MTC or MEN 2; contraindication for serious hypersensitivity to semaglutide/excipients).
Importance:
Moderate
No specific monitoring instructions were included (e.g., observe for acute pancreatitis; monitor renal function during volume depletion risk; guidance regarding severe GI reactions/gastroparesis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Extracted claims include multiple adverse reaction safety statements (and 'common' frequency framing) that are not supported by the provided label excerpts and appear to be mis-cited, plus several safety comparative 'higher risk vs placebo' statements that are unsupported in the provided evaluation. This creates elevated risk of misinforming safety and monitoring content relative to the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple core dosing/safety-related claims are unsupported or inconsistently evaluated against the provided label sections, including mis-citation/misattribution for adverse reactions and unsupported comparative/statistical framing (e.g., '2020 meta-analysis/study' and 'higher risk vs placebo').
Suggested Improvement
Remove or rephrase statements not explicitly supported by the supplied label excerpts (especially study-year/meta-analysis comparative claims and 'common adverse reactions' frequency claims). Align adverse reaction statements to the exact label sections that describe the adverse reaction content, and ensure dosing/administration claims are supported by the provided '2 DOSAGE AND ADMINISTRATION' excerpt.